Medicare-eligible patients with cutaneous squamous cell carcinoma (cSCC) could save on health care costs by utilizing the 40-gene expression profile (40-GEP) to guide treatment decisions.
Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2023 Earnings Call Transcript August 2, 2023 Castle Biosciences, Inc. misses on earnings expectations. Reported EPS is $-0.06 EPS, expectations were $1.01. Operator: Good afternoon, and welcome to Castle Biosciences Second Quarter 2023 Conference Call. As a reminder, today’s call is being recorded. We will begin today’s call with opening […]